REG - Tissue Regenix Group - Director/PDMR Shareholding

Tissue RegenixAnnouncement

15/09/2023 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230915:nRSO6628Ma&default-theme=true

RNS Number : 6628M  Tissue Regenix Group PLC  15 September 2023

Tissue Regenix Group plc

("Tissue Regenix", the "Company" or "the Group")

 

Director/PDMR Shareholding

 

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company,
announces that on 15 September 2023, Brian Phillips, Non-Executive Director,
bought 6,773 Ordinary Shares in the Group at a price of 54 pence per share for
a total consideration of £3,657.42.

 

As a result, Brian Phillips holds 160,000 Ordinary Shares in the Company
representing 0.23% of the total issued share capital.

 

Change of Name of Nominated Adviser and Broker

The Company also announces that its Nominated Adviser and Sole Broker has
changed its name to Cavendish Capital Markets Limited following completion of
its own corporate merger.

 

 

For more information:

 

 Tissue Regenix Group plc                                              www.tissueregenix.com (http://www.tissueregenix.com)
 David Cocke, Chief Financial Officer                                  via Walbrook PR

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)  Tel: +44 (0)20 7933 8780
 Alice Woodings/Lianne Applegarth   TissueRegenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries, and
wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Brian Phillips

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Tissue Regenix Group plc

 b)   LEI                                                           213800PNOD5UHQUFJI36

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.1p each

      Identification code                                          GB00B5SGVL29

 b)   Nature of the transaction                                    Purchase

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     0.54              6,773

 d)   Aggregated information

      - Aggregated volume                                          6,773

      - Price                                                      £3,657.42

 e)   Date of the transaction                                      15 September 2023

 f)   Place of the transaction                                     London Stock Exchange, AIM Market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBUGDCLDBDGXU